Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Common Equity (2021 - 2025)

Cardio Diagnostics Holdings' Common Equity history spans 5 years, with the latest figure at $8.2 million for Q3 2025.

  • For Q3 2025, Common Equity rose 121.14% year-over-year to $8.2 million; the TTM value through Sep 2025 reached $8.2 million, up 121.14%, while the annual FY2024 figure was $9.6 million, 223.1% up from the prior year.
  • Common Equity for Q3 2025 was $8.2 million at Cardio Diagnostics Holdings, down from $9.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $11.4 million in Q1 2025 and bottomed at $24279.0 in Q3 2021.
  • The 5-year median for Common Equity is $3.2 million (2023), against an average of $4.8 million.
  • The largest annual shift saw Common Equity skyrocketed 39337.4% in 2022 before it plummeted 76.1% in 2023.
  • A 5-year view of Common Equity shows it stood at $1.1 million in 2021, then skyrocketed by 302.74% to $4.3 million in 2022, then tumbled by 31.23% to $3.0 million in 2023, then skyrocketed by 223.1% to $9.6 million in 2024, then fell by 14.71% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for CDIO's Common Equity are $8.2 million (Q3 2025), $9.7 million (Q2 2025), and $11.4 million (Q1 2025).